期刊文献+

因卡膦酸二钠治疗骨转移癌的临床研究 被引量:5

Clinical study of incadronate disodium in the treatment of bone metastases cancer
下载PDF
导出
摘要 目的:评价因卡膦酸二钠治疗恶性肿瘤骨转移痛及改善活动能力的效果。方法:60例骨转移癌疼痛患者随机分为治疗组和对照组,治疗组单次静脉滴注因卡膦酸二钠10 mg,对照组单次静脉滴注帕米膦酸二钠60~90 mg,观察2周内患者骨痛及活动能力改善效果。结果:总有效率治疗组为86.7%,对照组为83.3%,2组止痛效果差异无统计学意义(P>0.05);治疗组和对照组改善患者活动能力的总有效率分别为76.7%和73.3%,2组差异无统计学意义(P>0.05);对照组的发热率为13.3%,治疗组无发热病例。结论:因卡膦酸二钠对于恶性肿瘤骨转移所引起的骨痛具有较好的治疗作用,可提高患者的活动能力。因卡膦酸二钠与帕米膦酸二钠骨痛缓解率、活动能力的改善基本相似,而因卡膦酸二钠的不良反应较轻。 Objective: To evaluate the curative effect of incadronate disodium on relieving pain and improving activity of daily living (ADL) of cancer patients with bone metastases. Methods: Sixty patients with bone metastases were randomly divided into the treatment group and the control group. Thirty patients in the treatment group (the incadronate group) received an intravenous infusion of incadronate disodium 10 mg, and the control group (the pamidronate group) received pamidronate 60-90 mg. The effects of relieving pain and improving ADL of cancer patients were evaluated in 2 weeks. Results: The response rates of bone pain relief were 86.7% and 83.3% in the incadronate and pamidronate group, respectively. There was no significant difference between two groups in bone pain relief ( P 〉 0.05). The total effective rates of improving ADL were 76.7% and 73.3% in incadronate group and pamidronate group, and there was no significant difference between two groups ( P 〉 0.05). The commom side-effect was transient pyrexia. The incidence rate of pyrexia was 13.3% in the control group, while no case of pyrexia was observed in the treatment group. Conclusion: lncadronate disodium was effective for relieving pain and improving ADL in cancer patients with bone metastases, which was similar to pamidronate, while the side-effect was mild.
作者 冯宇
出处 《中国药物应用与监测》 CAS 2011年第4期200-202,共3页 Chinese Journal of Drug Application and Monitoring
关键词 因卡膦酸二钠 帕米膦酸二钠 骨转移疼痛 Incadronate disodium Pamidronate disodium Bone metastases pain
  • 相关文献

参考文献6

二级参考文献18

  • 1杨莉,王亚非.芬太尼贴剂与硫酸吗啡控释片治疗癌痛临床观察[J].现代肿瘤医学,2004,12(6):563-565. 被引量:11
  • 2刘华,王蔚,郑垂志,邢雪花.癌症三阶梯止痛563例分析[J].中国肿瘤临床,2004,31(23):1346-1348. 被引量:79
  • 3汤钏猷.现代肿瘤学[M].上海:上海科技出版社,1993.537.
  • 4WellingtonK, GoaKL. Zoledronicacid : aofmalignancy. Drugs, 2003,63 (4) :417
  • 5Corso A, Ferretti E, Lunghi M , et al. Zoledronic acid downregu - lares adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. Canc-er ,2005 ,104(1) :118-125
  • 6Leto G, Badalamenti G, Arcara C, et al. Effects of zoledronic acidOn proteinase plasma levels in patients with bone metastases. Anticancer Res,2006 ,26(1A) :23 - 26
  • 7Delea T, Langer C, McKieman J , et al. The cost of treatment ofskeletal related events in patients with bone metastases from lung cancer. Oncology,2004 ,67 (5 , 6) :390 - 396
  • 8Mystakidou K, Katsouda E, Parpa E,et al. Randomized , open label , prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Meal Oncol ,2005 ,22(2) : 195- 201
  • 9Tanvetyanon T, Hines E Jr . Long - term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall ceil lung carcinoma and other solid tumors. Cancer ,2004 , 100 (12) :2613 -2621
  • 10Coleman RE. Bisphosphonates .. clinical experience[J].Oncologist, 2004,9(Suppl.4): 14 -27.

共引文献23

同被引文献18

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部